skip to content

 

A study in fruit flies reveals how aripiprazole, a common antipsychotic medication, has off-target effects on the intestine

15 April 2025

Researchers at the MRC Toxicology Unit have identified that the antipsychotic drug aripiprazole shows similar gastrointestinal side effects in fruit flies as in humans. For the first time they linked the mitochondria damaging effects of aripiprazole to death of the cells lining the intestine. Feeding the flies with an...

Read more

The Toxicology Unit joins two events at the Cambridge Festival

4 April 2025

Last week 25 researchers from the MRC Toxicology Unit took part in two events for the 2025 edition of the Cambridge Festival to share exciting facts about science and engage families with our research. CamFest-25.png The Cambr idge Festival is an annual event that was started over 20 years ago by scientists from the...

Read more

Unit researchers awarded prizes at the joint BTS-BPS Meeting

31 January 2025

Eve Stalker, a PhD student in the Willis Lab, and Dr Miriam Cipullo, a Postdoctoral Fellow joint between AstraZeneca and the MacFarlane Lab at the MRC Toxicology Unit were awarded prizes at the joint BTS-BPS Meeting ‘Toxicology in a New Era of Pharmacology’. The one-day conference brought together experts across...

Read more

Researchers identify new link between mitochondrial dysfunction and the development of COPD

20 December 2024

Researchers in the MacFarlane lab at the MRC Toxicology Unit have identified that a protein called TAp73 controls mitochondrial function in ciliated cells that line our airways. Ciliated cells are essential to clear mucus from our airways to maintain lung function. As this process is defective in diseases such as Chronic...

Read more

Anne Willis awarded the John Barnes Prize for 2025

6 December 2024

Our Unit Director Prof Anne Willis has been awarded the prestigious John Barnes Prize Award from the British Toxicology Society . Prof Willis leads a research group investigating the role of post-transcriptional control in response to toxic injury with a focus on RNA-binding proteins, regulatory RNA motifs and tRNAs and...

Read more

Unit comes together at our Annual Science Day

28 November 2024

Earlier this month, all Unit colleagues came together to celebrate our science and achievements over the last year. This year we had talks from each of our Group Leaders who shared overviews of the direction of their group's work, as well as a handful of talks from postdoctoral researchers and PhD students about their...

Read more

Unit attends Big Biology Day 2024

5 November 2024

Researchers from the Unit took part in the Big Biology Day at Hills Road Sixth Form College on 12th October. We brought along our Human Bookshelf activity and turned 8 of our scientists into 'human books' for the day. Visitors were able to loan our books for conversations about their research topics, what it is like to be...

Read more

Art and science come together to showcase Toxicology Unit research

16 September 2024

Throughout 2024, members of the public have been invited into the Toxicology Unit to create prints based on their interpretations of our research. In collaboration with Curwen Print Study Centre, we hosted five printmaking workshops between March and September. Each workshop was hosted by a different researcher who...

Read more

Willis & Thaventhiran join BBC Inside Health to discuss cancer 'vaccines'

27 August 2024

Trials of a cancer 'vaccine' have begun. The vaccine is based on the same mRNA technology as the Pfizer-BioNTech COVID-19 vaccines. As part of this latest episode of BBC Radio 4's Inside Health programme, James Gallagher visits the Unit and speaks to Prof Anne Willis and Dr James Thaventhiran about how the vaccine is...

Read more

New technology enables faster response to disease outbreaks like COVID-19

15 August 2024

New research from the Thaventhiran lab in collaboration with the groups of Florian Hollfelder , Marko Hyvonen , Nick Matheson and Charlotte Deane establishes a new, generalised technology for finding potentially therapeutic antibodies in response to infectious disease outbreaks faster than currently possible.

Read more